Spike Protein Targeting" Nano-Glue" that Captures and Promotes SARS-CoV-2 Elimination

G Zhang,Y Cong,G Cao,L Li,P Yu,Q Song,K Liu,J Qu,J Wang,W Xu
DOI: https://doi.org/10.1101/2021.04.13.439641
2021-01-01
Abstract:The global emergency caused by the SARS-CoV-2 pandemics can only be solved with adequate preventive and therapeutic strategies, both currently missing. The electropositive Receptor Binding Domain (RBD) of SARS-CoV-2 spike protein with abundant β-sheet structure serves as target for COVID-19 therapeutic drug design. Here, we discovered that ultrathin 2D CuInP2S6 (CIPS) nanosheets as a new agent against SARS-CoV-2 infection, which also able to promote viral host elimination. CIPS exhibits extremely high and selective binding capacity with the RBD of SARS-CoV-2 spike protein, with consequent inhibition of virus entry and infection in ACE2-bearing cells and human airway epithelial organoids. CIPS displays nano-viscous properties in selectively binding with spike protein ( KD < 1 pM) with negligible toxicity in vitro and in vivo . Further, the CIPS-bound SARS-CoV-2 was quickly phagocytosed and eliminated by macrophages, suggesting CIPS could be successfully used to capture and facilitate the virus host elimination with possibility of triggering anti-viral immunization. Thus, we propose CIPS as a promising nanodrug for future safe and effective anti-SARS-CoV-2 therapy, as well as for use as disinfection agent and surface coating material to constrain the SARS-CoV-2 spreading. ### Competing Interest Statement The authors have declared no competing interest.
What problem does this paper attempt to address?